Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 May 21;8(22):19302-19310.
doi: 10.1021/acsomega.2c08135. eCollection 2023 Jun 6.

Optimization of Chitosan-Decorated Solid Lipid Nanoparticles for Improved Flurbiprofen Transdermal Delivery

Firdous Ahmad Burki  1 , Kifayat Ullah Shah  1 , Ghulam Razaque  2 , Shefaat Ullah Shah  1 , Asif Nawaz  1 , Muhammad Danish Saeed  1 , Maqsood Ur Rehman  3 , Hadia Bibi  4 , Mulham Alfatama  5 , Tarek M Elsayed  5
Affiliations

Optimization of Chitosan-Decorated Solid Lipid Nanoparticles for Improved Flurbiprofen Transdermal Delivery

Firdous Ahmad Burki et al. ACS Omega. .

Abstract

Transdermal delivery is a potential alternative route to oral administration for drugs associated with stomach discomfort, such as flurbiprofen, a widely nonsteroidal anti-inflammatory drug (NSAID). This study aimed to design solid lipid nanoparticle (SLN) transdermal formulations of flurbiprofen. Chitosan-coated SLNs were prepared by the solvent emulsification method, and their properties and permeation profiles across the excised rat skin were characterized. The particle size of uncoated SLNs was at 695 ± 4.65 nm, which increased to 714 ± 6.13, 847 ± 5.38, and 900 ± 8.65 nm upon coating with 0.05, 0.10, and 0.20% of chitosan, respectively. The drug association efficiency was improved when a higher concentration of chitosan was employed over SLN droplets that endowed a higher affinity of flurbiprofen with chitosan. The drug release was significantly retarded as compared to the uncoated entities and followed non-Fickian anomalous diffusion that was depicted by "n" values of >0.5 and <1. Also, the total permeation of chitosan-coated SLNs (F7-F9) was significantly higher than that of the noncoated formulation (F5). Overall, this study has successfully designed a suitable carrier system of chitosan-coated SLNs that provide insight into the current conventional therapeutic approaches and suggest new directions for the advancements in transdermal drug delivery systems for improved permeation of flurbiprofen.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing financial interest.

Figures

Figure 1
Figure 1
Scanning electron microscopy images of SLNs (F5) and SLN-coated chitosan (F7, F8, F9).
Figure 2
Figure 2
Cumulative percentage drug release from manufactured SLNs.
Figure 3
Figure 3
Cumulative permeation percentage of the drug through the skin.
Figure 4
Figure 4
FTIR spectra of (a) F5, (b) F7, (c) F8, (d) F9, (e) chitosan, and (f) flurbiprofen.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Bariya S. H.; Gohel M. C.; Mehta T. A.; Sharma O. P. Microneedles: An Emerging Transdermal Drug Deliveryery System. J. Pharm. Pharmacol. 2011, 64, 11–29. 10.1111/j.2042-7158.2011.01369.x. - DOI - PubMed
    1. Garg T.; Rath G.; Goyal A. K. Comprehensive Review on Additives of Topical Dosage Forms for Drug Deliveryery. Drug Delivery 2015, 22, 969–987. 10.3109/10717544.2013.879355. - DOI - PubMed
    1. Radwan-Pragłowska J.; Janus Ł.; Piątkowski M.; Sierakowska A.; Matysek D. ZnO Nanorods Functionalized with Chitosan Hydrogels Crosslinked with Azelaic Acid for Transdermal Drug Deliveryery. Colloids Surf., B 2020, 194, 11117010.1016/j.colsurfb.2020.111170. - DOI - PubMed
    1. Chaturvedi S.; Garg A. An Insight of Techniques for the Assessment of Permeation Flux across the Skin for Optimization of Topical and Transdermal Drug Deliveryery Systems. J. Drug Delivery Sci. Technol. 2021, 62, 10235510.1016/j.jddst.2021.102355. - DOI
    1. Long L.-y.; Zhang J.; Yang Z.; Guo Y.; Hu X.; Wang Y. Transdermal Delivery of Peptide and Protein Drugs: Strategies, Advantages and Disadvantages. J. Drug Delivery Sci. Technol. 2020, 60, 10200710.1016/j.jddst.2020.102007. - DOI